

Novartis India Limited

Regd. off: Sandoz House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai 400 018.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2010

| Sr. No | . Particulars | Quarter ended 30.06.201 | ended 0 30.06.200 | Rupees Milli Year ended 9 31.03.201 |
|--------|---|-------------------------------|----------------------|--|
| 1. | (a) N-t-C-1 | (Unaudited | (Unaudited |) (Audited) |
| 1. | (a) Net Sales | | | |
| 2. | (b) Other Operating Income | 1,682. | | 6,241. |
| 3. | Income from Operations | 88. | | |
| 3. | Expenditure | 1,771. | 1,612.4 | 6,582. |
| | (a) (Increase)/Decrease in stock-in-trade and work-in-progress (b) Consumption of raw materials | 17.4 | | 7,502, |
| - 1 | (c) Purchases of traded goods | 33.0 | 35.0 | |
| 1 | (d) Employees cost | 597.4 | 33.9 | 1/2.0 |
| - 1 | (e) Depreciation | 307.0 | 000.5 | 2,011.0 |
| | (f) Other expenditure | 4.7 | 200.4 | 0.01.0 |
| | | 457.5 | 3.0 | 22.5 |
| 4. | Profit from operations I Sub-total | 1,417.0 | 703.1 | 1,866.9 |
| 5. | Profit from operations before Other Income and Interest Other Income | 354.7 | 1-2113 | 5,219.4 |
| 6. F | Profit before Interest | 120.8 | 334.3 | 1,362.9 |
| 7. I | nterest | 475.5 | 100.7 | 438.3 |
| | | | 000.0 | 1,801.2 |
| 9. T | Profit from ordinary activities before taxation Tax Expense | 0.6 | 0.7 | 3.2 |
| | Current tax | 474.9 | 502.9 | 1,798.0 |
| _ | Deferred tax | 162.0 | | 7.36 |
| - | Frings have State | 162.0 | 176.0 | 654.2 |
| 10. N | Fringe benefits tax | (2.4) | (1.3) | (16.1) |
| | et Profit | 245.5 | 10.6 | - |
| 12. R | ald-up equity share capital (face value Rs. 5 each) | 315.3 | 317.6 | 1,159.9 |
| | | 159.8 | 159.8 | 159.8 |
| | To Stidle - Basic and Diller to | | | 5,774.8 |
| ar | nnualised) | 9.87 | 9.94 | 36.29 |
| 4. Pt | ublic Shareholding | | | |
| - 1 | Number of shares | | | |
| | Percentage of shareholding | 7,535,995 | 7,535,995 | 7,535,995 |
| 5. Pr | omoter and promoter group shareholding | 23.58 | 23.58 | 23.58 |
| 1(0 |) Fleuded / Enclimbered | | | 23.36 |
| - r | Number of shares | | | 1 |
| - F | Percentage of shares (as a % of the total shareholding of | - | _ | |
| pro | omoter and promoter group) | | | 3.00 |
| | | _ | | 1 |
| the | Percentage of shares (as a % of the total share capital of | | - | - |
| (b | Non-encumbered | | | |
| | umber of shares | - | - | _ |
| 1,10 | uniber of shares | 24 424 000 | | |
| - P | ercentage of shares (as a % of the total shareholding of | 24,424,802 | 24,424,802 | 24,424,802 |
| | | 100.00 | 100.00 | 100.00 |
| - Pe | ercentage of shares (as a % of the total share capital of | | 10000 | 100.00 |
| tho | company company | 76.42 | 76.42 | |



Novartis India Limited

Regd. off: Sandoz House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai 400 018.

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED

| | | Rupees Millie | | |
|----------------------|--|---------------|---|----------------|
| Sr. No. | | Quarter | Quarter | Year |
| | | ended | ended | ended |
| | Particulars Particulars | 30.06.2010 | 30.06.2009 | 31.03.201 |
| 1. | Segment revenue | (Unaudited) | (Unaudited) | (Audited) |
| | (a) Pharmaceuticals | | 4477.0000000000000000000000000000000000 | |
| | (b) Generics | 1,221.9 | 1,126.2 | 4,373. |
| | (c) OTC | 112.0 | 107.9 | 399. |
| | (d) Animal Health | 199.4 | 169.5 | 859. |
| | Net sales | 149.5 | 128.2 | 609. |
| | | 1,682.8 | 1,531.8 | 6,241. |
| | Segment results before interest and taxation | | | |
| | (a) Pharmaceuticals | 359.1 | 387.4 | 1 204 |
| | (b) Generics | 44.9 | 33.6 | 1,294. 111. |
| | (c) OTC | (10.6) | (3.6) | 33. |
| | (d) Animal Health | 13.3 | 12.3 | 82. |
| | Total Add/(Less): | 406.7 | 429.7 | 1,521. |
| | (a) Interest | | | 1,321. |
| | (b) Other unallocable expenditure | (0.6) | (0.7) | (3. |
| | (c) Other unallocable income | (54.4) | (40.6) | (176. |
| | | 123.2 | 114.5 | 456. |
| | Total profit before taxation | 474.9 | 502.9 | 1,798. |
| () () () () | Capital employed | | | =1.50. |
| | (Segment assets less segment liabilities) | | 1 | |
| | (a) Pharmaceuticals | | | |
| | (b) Generics | 194.2 | 395.9 | 444. |
| | (c) OTC | 40.2 | 26.9 | 18.0 |
| | (d) Animal Health | 46.8 | 64.3 | 56.4 |
| | Total | 163.1 | 130.7 | 175.5 |
| | Add: Unallocable corporate assets less unallocable | 444.3 | 617.8 | 694.3 |
| | corporate liabilities | F 00F - | | |
| | Total capital employed | 5,805.6 | 4,847.2 | 5,240.3 |
| | | 6,249.9 | 5,465.0 | 5,934.6 |



Notes:

- 1. The above results were reviewed by the Audit Committee at its meeting held on 29th July 2010 and approved at the meeting of the Board of Directors held on that date.
- 2. The results for the quarter ended 30th June 2010 have been subjected to limited review by the statutory auditors of the company.
- Consequent to the amendment to the provisions of sub-section (3) of Section 4 of the Payment of Gratuity Act, 1972 revising the ceiling limit
 of gratuity payable to employees from rupees three lakhs fifty thousand to rupees ten lakhs, during the quarter, the company has made a
 further provision of Rs 46.5 million, towards the past service cost, on the basis of valuation carried out by independent actuary.
- 4. During the quarter, 2 investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the quarter.

5. Figures for the prior periods have been regrouped where necessary.

By Order of the Board

Vice Chairman and Managing Director

Mumbai, 29th July 2010